PLx Pharma Inc (PLXP)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013957)
◆英語タイトル:PLx Pharma Inc (PLXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013957
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:41
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
PLx Pharma Inc (PLx Pharma) is a drug development company that develops patent-protected delivery systems. The company’s products include PLxGuard delivery system, PLxGuard pipeline products, PL2200 aspirin and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in enhancement of efficacy of drugs, GI safety development, new or extended patent protection, and new drug application solutions. PLx Pharma offers publications and research services. The company serves for severe pain and cardiovascular market. It caters its products and services to healthcare professionals. PLx Pharma is headquartered in Houston, Texas, the US.

PLx Pharma Inc (PLXP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PLx Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
PLx Pharma Raises USD1.3 Million in Venture Financing 12
PLx Pharma Raises USD9 Million in Extended Series E Financing 13
PLx Pharma Raises USD8.27 Million in Series E Financing 14
PLx Pharma Secures US$2.9 Million In Series F Round 15
Merger 16
Dipexium Pharma Merges with PLx Pharma 16
Licensing Agreements 18
PLx Pharma Enters into Licensing Agreement with Lee’s Pharma for Cardiovascular Product 18
Equity Offering 19
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 19
PLx Pharma Withdraws IPO 20
PLx Pharma Inc – Key Competitors 22
PLx Pharma Inc – Key Employees 23
PLx Pharma Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Nov 09, 2017: PLx Pharma Reports Third Quarter 2017 Results 25
Aug 10, 2017: PLx Pharma Reports Second Quarter 2017 Results 27
May 02, 2017: Rita M. O Connor Appointed Chief Financial Officer of PLx Pharma 28
Corporate Communications 29
May 01, 2017: PLx Pharma appoints vice president of sales and marketing 29
Jan 04, 2016: PLx Pharma Appoints Natasha Giordano as CEO 30
Product News 31
06/20/2016: Dipexium Pharmaceuticals Locilex Microbiology Data Presented at ASM Microbe 2016 Conference 31
05/10/2017: PLx Pharma Receives NCI Grant for Research of Novel Aspirin Formulation to Prevent Colorectal Cancer 32
05/01/2017: PLx Pharma Appoints Michael J. Dillon as Vice President, Sales and Marketing 33
Product Approvals 34
Oct 04, 2016: Dipexium Receives European Medicines Agency Designation as a Small and Medium Enterprise 34
Clinical Trials 35
Feb 14, 2017: PLx Pharma Announces Publication of Positive Antiplatelet Data for Aspertec in Peer-Reviewed Medical Journal JACC 35
Oct 25, 2016: Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound Care 36
Oct 20, 2016: Dipexium Provides Update on Availability of Results from Pivotal Phase 3 Clinical Trials with Locilex 37
May 16, 2016: Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial 38
May 12, 2016: Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial 39
Feb 04, 2016: Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
PLx Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2014 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PLx Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PLx Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PLx Pharma Raises USD1.3 Million in Venture Financing 12
PLx Pharma Raises USD9 Million in Extended Series E Financing 13
PLx Pharma Raises USD8.27 Million in Series E Financing 14
PLx Pharma Secures US$2.9 Million In Series F Round 15
Dipexium Pharma Merges with PLx Pharma 16
PLx Pharma Enters into Licensing Agreement with Lee's Pharma for Cardiovascular Product 18
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 19
PLx Pharma Withdraws IPO 20
PLx Pharma Inc, Key Competitors 22
PLx Pharma Inc, Key Employees 23

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ PLx Pharma Inc (PLXP)-製薬・医療分野:企業M&A・提携分析(PLx Pharma Inc (PLXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆